![PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib](https://www.researchgate.net/publication/363193523/figure/fig2/AS:11431281082626222@1662086926570/Overall-survival-from-time-of-CLL-progression-on-ibrutinib-by-line-of-therapy-A-It_Q320.jpg)
PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
![Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study | SpringerLink Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00277-021-04536-6/MediaObjects/277_2021_4536_Fig4_HTML.png)
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study | SpringerLink
![Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study | SpringerLink Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00277-021-04536-6/MediaObjects/277_2021_4536_Fig1_HTML.png)
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study | SpringerLink
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial | Haematologica
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial | Haematologica
![Cancers | Free Full-Text | The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions Cancers | Free Full-Text | The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions](https://pub.mdpi-res.com/cancers/cancers-14-00771/article_deploy/html/images/cancers-14-00771-g001.png?1643800082)
Cancers | Free Full-Text | The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions
![PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib](https://www.researchgate.net/publication/363193523/figure/fig3/AS:11431281082645657@1662086926602/Overall-survival-following-Richter-transformation-on-ibrutinib-by-line-of-therapy-A-It_Q320.jpg)
PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
![ABBVIE: IMBRUVICA® (ibrutinib) Plus GAZYVA® (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint | American Pharmacy News ABBVIE: IMBRUVICA® (ibrutinib) Plus GAZYVA® (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint | American Pharmacy News](https://s3.amazonaws.com/jnswire/jns-media/ef/93/822887/AbbVie-Logo-EPS-vector-image.png)
ABBVIE: IMBRUVICA® (ibrutinib) Plus GAZYVA® (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint | American Pharmacy News
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial | Haematologica
![Long‐term efficacy of first‐line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials - Allan - 2022 - British Journal of Haematology - Long‐term efficacy of first‐line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials - Allan - 2022 - British Journal of Haematology -](https://onlinelibrary.wiley.com/cms/asset/377a2434-4dd7-4d0a-a163-be0a18d88012/bjh17984-fig-0001-m.jpg)
Long‐term efficacy of first‐line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials - Allan - 2022 - British Journal of Haematology -
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial | Haematologica
![Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial - The Lancet Oncology Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/538841af-7906-48ec-9670-f4233ac0b06a/gr1_lrg.gif)
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial - The Lancet Oncology
![Data Presented at ASH 2018 Provide Evidence of First-line Treatment Benefits with IMBRUVICA®▽ (ibrutinib)-Based Therapy Across All Patient Populations in CLL | Business Wire Data Presented at ASH 2018 Provide Evidence of First-line Treatment Benefits with IMBRUVICA®▽ (ibrutinib)-Based Therapy Across All Patient Populations in CLL | Business Wire](https://mms.businesswire.com/media/20181205005382/en/693858/23/Janssen_Logo_JJ.jpg)
Data Presented at ASH 2018 Provide Evidence of First-line Treatment Benefits with IMBRUVICA®▽ (ibrutinib)-Based Therapy Across All Patient Populations in CLL | Business Wire
![Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study | SpringerLink Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00277-021-04536-6/MediaObjects/277_2021_4536_Fig3_HTML.png)
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study | SpringerLink
![Cancers | Free Full-Text | An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted Therapy Cancers | Free Full-Text | An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted Therapy](https://www.mdpi.com/cancers/cancers-12-00894/article_deploy/html/images/cancers-12-00894-g001.png)